(Total Views: 420)
Posted On: 09/04/2025 6:46:20 PM
Post# of 156696
The top-selling PD-L1/PD-1 inhibitors are Keytruda (pembrolizumab) and Opdivo (nivolumab), which together dominated the market in 2021 and were the leading drugs by revenue in subsequent years, with Keytruda being the top-selling drug globally by 2023. Other significant PD-1/PD-L1 inhibitors include Tecentriq (atezolizumab), Imfinzi (durvalumab), and Libtayo (cemiplimab).
Opdivo
(nivolumab): Developed by Bristol Myers Squibb, Opdivo is the other leading PD-1 inhibitor, generating approximately $9 billion in sales in 2023.
Tecentriq
(atezolizumab): This PD-L1 inhibitor from Roche was another top seller in 2023, bringing in over $4 billion in revenue.
Imfinzi
(durvalumab): AstraZeneca's PD-L1 inhibitor also had strong sales, exceeding $4 billion in 2023.
Opdivo
(nivolumab): Developed by Bristol Myers Squibb, Opdivo is the other leading PD-1 inhibitor, generating approximately $9 billion in sales in 2023.
Tecentriq
(atezolizumab): This PD-L1 inhibitor from Roche was another top seller in 2023, bringing in over $4 billion in revenue.
Imfinzi
(durvalumab): AstraZeneca's PD-L1 inhibitor also had strong sales, exceeding $4 billion in 2023.
(3)
(0)
